Synthetic biology in cell-based cancer immunotherapy.
Synthetic biology in cell-based cancer immunotherapy.
复制标题
DOI：
10.1016/j.tibtech.2015.05.001
复制
发表时间：
2015-08
影响因子：
17.3
通讯作者：
Wong WW
中科院分区：
文献类型：
--
作者：
Chakravarti D;Wong WW
具有癌症靶向受体的基因工程T细胞的过继转移在临床试验中显示出根除肿瘤的巨大希望。这种形式的细胞免疫治疗提供了一个独特的机会，将先进的系统和合成生物学方法结合起来，创造出具有新功能的癌症治疗方法。在这里，我们首先回顾了用于控制T细胞抗肿瘤活性的位置、持续时间和强度的合成受体、开关和电路的发展。此外，我们还讨论了宿主细胞（或底盘）的细胞工程和基因组编辑，以提高基于细胞的癌症治疗的疗效，并减少制造的时间和成本。
The adoptive transfer of genetically engineered T cells with cancer-targeting receptors has shown tremendous promise for eradicating tumors in clinical trials. This form of cellular immunotherapy presents a unique opportunity to incorporate advanced systems and synthetic biology approaches to create cancer therapeutics with novel functions. Here, we first review the development of synthetic receptors, switches, and circuits to control the location, duration, and strength of T cell activity against tumors. In addition, we discuss the cellular engineering and genome editing of host cells (or the chassis) to improve the efficacy of cell-based cancer therapeutics, and to reduce the time and cost of manufacturing.